[go: up one dir, main page]

UY23935A1 - Formas de dosificación de azitromicina que no presentan efecto alimento adverso con la comida - Google Patents

Formas de dosificación de azitromicina que no presentan efecto alimento adverso con la comida

Info

Publication number
UY23935A1
UY23935A1 UY23935A UY23935A UY23935A1 UY 23935 A1 UY23935 A1 UY 23935A1 UY 23935 A UY23935 A UY 23935A UY 23935 A UY23935 A UY 23935A UY 23935 A1 UY23935 A1 UY 23935A1
Authority
UY
Uruguay
Prior art keywords
azithromycin
tablet
food
dosage form
dosage forms
Prior art date
Application number
UY23935A
Other languages
English (en)
Inventor
J Curatolo William
H Foulds George
L Friedman Hylar
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY23935(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of UY23935A1 publication Critical patent/UY23935A1/es
Priority to UY24614A priority Critical patent/UY24614A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se describe una forma de dosificación en la forma de una tableta que comprende azitromicina, en donde dicha tableta es administrable a un mamífero que ha comido y la cual no exhibe efectos adversos a la comida, que incluye: azitromicina, un desintegrante y opcionalmente otros ingredientes, mezclados y granulado en húmedo, previo a la formación de la mencionada tableta, donde dicha tableta lleva adelante la disolución de por lo menos un 90% de la azitromicina en aproximadamente 30 minutos cuando una cantidad de tal forma de dosificación equivalente a 200 mg de azitromicina se ensaya conforme al Ensayo USO < 711 > en un aparato de disolución USP-2 bajo condiciones tan severas como las siguientes: - 900 ml de buffer de fosfato de sodio, - pH 6, - 37º C, - con paletas que giran a 100 rpm, considerando que dicha forma de dosificación contiene una cantidad de un óxido o hidróxido de metal alcalino-terreo menor que la suficienta para quedar enmascarada a gusto. La azitromicina es de utilidad para el tratamiento de infecciones microbianas.
UY23935A 1994-04-29 1995-03-15 Formas de dosificación de azitromicina que no presentan efecto alimento adverso con la comida UY23935A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY24614A UY24614A1 (es) 1994-04-29 1997-07-10 Procedimiento para preparar formas de dosificacion de azitromicina

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (1)

Publication Number Publication Date
UY23935A1 true UY23935A1 (es) 1995-09-12

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
UY23935A UY23935A1 (es) 1994-04-29 1995-03-15 Formas de dosificación de azitromicina que no presentan efecto alimento adverso con la comida

Country Status (31)

Country Link
US (2) US5605889A (es)
EP (1) EP0679400B1 (es)
JP (3) JPH07300420A (es)
KR (1) KR100354310B1 (es)
CN (1) CN1088362C (es)
AP (1) AP566A (es)
AT (1) ATE183395T1 (es)
AU (1) AU709328B2 (es)
CA (1) CA2148071C (es)
CO (1) CO4560547A1 (es)
DE (1) DE69511451T2 (es)
DK (1) DK0679400T3 (es)
DZ (1) DZ1877A1 (es)
ES (1) ES2136247T3 (es)
FI (1) FI952060L (es)
GR (1) GR3031290T3 (es)
HU (1) HUT75244A (es)
IL (1) IL113437A (es)
LV (1) LV10918B (es)
MA (1) MA23533A1 (es)
NO (1) NO314386B1 (es)
NZ (1) NZ548384A (es)
OA (1) OA10151A (es)
RU (1) RU2128998C1 (es)
SI (1) SI0679400T1 (es)
TN (1) TNSN95046A1 (es)
TW (1) TW499311B (es)
UA (1) UA34464C2 (es)
UY (1) UY23935A1 (es)
YU (1) YU49483B (es)
ZA (1) ZA953439B (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0758244B2 (en) * 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
HU227938B1 (en) * 1995-02-08 2012-06-28 Astellas Pharma Europ B V Oral dosage-forms containing a beta-lactam antibiotic and process for producing them
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
EP0991415B1 (en) * 1997-12-22 2003-03-12 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
EP1169024B1 (en) * 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
CA2417353C (en) * 2000-07-25 2009-09-01 Laboratorio Silanes,S.A. De C.V. Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1)hexadeca-1(2)-en-8-one, and obtaining a new form of 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin a
WO2002015842A2 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
AU2002232406C1 (en) * 2000-11-06 2009-03-05 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
JP3836790B2 (ja) * 2000-11-15 2006-10-25 昌雄 菅又 子宮内膜症の予防又は治療薬
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
GEP20084399B (en) * 2001-05-22 2008-06-10 Pfizer Prod Inc Crystal forms of azithromycin
EP1652851A1 (en) 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
EA200400214A1 (ru) * 2001-08-21 2004-06-24 Пфайзер Продактс Инк. Азитромицин в виде разовой дозы
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
IL161398A0 (en) * 2001-10-18 2004-09-27 Teva Pharma Stabilized azithromycin compositions
AU2002353316A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Methods for wet granulating azithromycin
WO2003053416A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
EP1476191A2 (en) * 2002-01-16 2004-11-17 Pepgen Corporation Oral administration of interferon-tau
RU2283092C2 (ru) * 2002-02-01 2006-09-10 Пфайзер Продактс Инк. Сухие гранулированные композиции азитромицина
RU2203670C1 (ru) * 2002-02-19 2003-05-10 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Лекарственный препарат антибактериального действия и способ его получения
JP2005527508A (ja) * 2002-03-07 2005-09-15 ヴェクトゥラ　リミテッド 経口デリバリー用急速溶融多粒子製剤
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
EP1594762A1 (en) * 2003-02-19 2005-11-16 Teva Pharmaceutical Industries Limited Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
RU2241985C1 (ru) * 2003-03-27 2004-12-10 Томский политехнический университет Способ количественного определения азитромицина дигидрата методом инверсионной вольтамперометрии
EP1620111A4 (en) * 2003-05-06 2012-03-21 Nirmal Mulye FORMULATION OF ERYTHROMYCIN DERIVATIVES WITH CONTROLLED RELEASE
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DE602004019288D1 (de) * 2003-07-24 2009-03-19 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform
AR045142A1 (es) 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
EP1689368B1 (en) * 2003-12-04 2016-09-28 Bend Research, Inc Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions
AU2004294818A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
EP1691786A1 (en) * 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
UA78793C2 (en) * 2003-12-04 2007-04-25 Pfizer Prod Inc Oral dosage form of azitromycin with decreased side effects
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
NZ556630A (en) * 2005-01-27 2010-12-24 Alembic Ltd Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer
CA2600623A1 (en) * 2005-03-07 2006-09-14 Teva Pharmaceutical Industries Ltd. Azithromycin powder for oral suspension compositions
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
CN101184489B (zh) 2005-05-26 2011-01-19 大日本住友制药株式会社 药物组合物
JP5366233B2 (ja) * 2005-08-10 2013-12-11 塩野義製薬株式会社 口腔内崩壊錠剤
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
GB0618966D0 (en) * 2006-09-26 2006-11-08 Iti Scotland Ltd Cartridge system
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
SG11201404595TA (en) 2012-02-06 2014-09-26 Merial Ltd Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
US10092651B2 (en) 2012-02-28 2018-10-09 Seoul Pharma Co., Ltd. High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
CA2939604A1 (en) * 2013-11-11 2015-05-14 Forest Laboratories Holdings Limited Compositions and methods of treatment comprising fosfomycin disodium
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RU2066324C1 (ru) 1987-07-09 1996-09-10 Пфайзер Инк. Кристаллический дигидрат азитромицина и способ его получения
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0553353A1 (en) * 1990-10-15 1993-08-04 Taisho Pharmaceutical Co. Ltd 2'-modified erythromycin or derivative thereof
TW271400B (es) 1992-07-30 1996-03-01 Pfizer
JPH09503504A (ja) 1993-10-01 1997-04-08 ザ、プロクター、エンド、ギャンブル、カンパニー 成人歯周炎の治療のためのアジトロマイシンの用途とこの用途のための局所組成物
EP0758244B2 (en) 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin

Also Published As

Publication number Publication date
USRE39149E1 (en) 2006-06-27
AP566A (en) 1996-11-22
EP0679400A1 (en) 1995-11-02
CA2148071A1 (en) 1995-10-30
DZ1877A1 (fr) 2002-02-17
AU1771195A (en) 1995-11-09
KR100354310B1 (ko) 2002-12-26
CN1088362C (zh) 2002-07-31
YU49483B (sh) 2006-08-17
MA23533A1 (fr) 1995-12-31
LV10918B (en) 1996-06-20
ATE183395T1 (de) 1999-09-15
AU709328B2 (en) 1999-08-26
RU95106639A (ru) 1997-01-20
FI952060A7 (fi) 1995-10-30
NO951630L (no) 1995-10-30
FI952060A0 (fi) 1995-04-28
RU2128998C1 (ru) 1999-04-20
DE69511451T2 (de) 1999-12-09
SI0679400T1 (en) 1999-10-31
GR3031290T3 (en) 1999-12-31
US5605889A (en) 1997-02-25
JP2005015466A (ja) 2005-01-20
KR950028764A (ko) 1995-11-22
YU27195A (sh) 1999-03-04
NO314386B1 (no) 2003-03-17
IL113437A0 (en) 1995-07-31
OA10151A (en) 1996-12-18
ES2136247T3 (es) 1999-11-16
HUT75244A (en) 1997-05-28
UA34464C2 (uk) 2001-03-15
HU9501206D0 (en) 1995-06-28
TNSN95046A1 (fr) 1996-02-06
JPH07300420A (ja) 1995-11-14
EP0679400B1 (en) 1999-08-18
NZ548384A (en) 2008-04-30
LV10918A (lv) 1995-12-20
AP9500728A0 (en) 1995-04-30
IL113437A (en) 2001-04-30
CA2148071C (en) 2000-10-17
DE69511451D1 (de) 1999-09-23
JP2008231120A (ja) 2008-10-02
ZA953439B (en) 1996-10-28
DK0679400T3 (da) 1999-12-06
NO951630D0 (no) 1995-04-28
FI952060L (fi) 1995-10-30
CN1114879A (zh) 1996-01-17
CO4560547A1 (es) 1998-02-10
TW499311B (en) 2002-08-21

Similar Documents

Publication Publication Date Title
UY23935A1 (es) Formas de dosificación de azitromicina que no presentan efecto alimento adverso con la comida
PT1246920E (pt) Prevenção de afecções associadas ao circovírus porcino 2
CA2498143A1 (en) Antimicrobial composition and method for use
BG104644A (en) Novel macrolides
US3436454A (en) Antipyretic and antirheumatic compositions containing an animal mucin
PE20010977A1 (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
CN104830578B (zh) 一种高效洁厕剂及其制备方法
BR9913738A (pt) Composições e métodos de sanitização
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
Rey Moreno et al. Epoxiconazole‐induced degeneration in rat placenta and the effects of estradiol supplementation
PH12020551412A1 (en) Pharmaceutical composition including sodium alkyl sulfate
US2649398A (en) Douche composition
SE9802818D0 (sv) Surdegsprodukt
WO2018083212A1 (en) Microbiome-safe cosmetic cleaning compositions
Peterson et al. Toxicity of Echium plantagineum (Paterson's Curse). 2. Pyrrolizidine alkaloid poisoning in rats
IE40957L (en) 4- o-ó,d-glucopyranosyl -6-o-ó,d- xylohexopyranosyl -2-¹deoxystreptamine
Hellbaum et al. Action of estrogen on release of hypophyseal luteinizing hormone
Russo et al. The enigma of testicular leukemia: a critical review
UA27142C2 (uk) Фармацевтичhа композиція
KR970020112A (ko) 결명자 추출물의 제조방법과 이들로된 항산화, 프리라디칼소거, 항돌연변이제 및 안(眼) 노화 방지 안질환예방제
NO125986B (es)
KR101889958B1 (ko) 물비누를 이용한 친환경 소화약제와 이의 제조방법
EFSA Panel on Biological Hazards (BIOHAZ) Scientific Opinion on the evaluation of the safety and efficacy of Cecure® for the removal of microbial surface contamination of raw poultry products
US3694366A (en) Detergent solutions
JP7073436B2 (ja) 洗浄用組成物

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20150315